Compositions and methods for expressing otoferlin

Abstract

To provide methods and compositions for expressing Otoferlin, e.g., utilizing adeno-associated viral (AAV) particles.SOLUTION: Such methods and compositions may be useful for treatment of diseases such as deafness, autosomal recessive 9 (DFNB9).

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 502,462, filed May 5, 2017, the entire disclosure of which is incorporated herein by reference. Federally funded research This invention was made with Government support under Grant Nos. EY000331, EY021721, and DC012118 awarded by the National Institutes of Health. The Government has certain rights in the invention. [Background technology]

[0002] 2. Background of the Invention Nonsyndromic hearing loss is a type of hearing loss that is generally caused by defects or damage to the inner and / or middle ear. Mutations in the OTOF gene, which encodes the protein otoferlin, are thought to cause a type of nonsyndromic hearing loss called "Deafness, Autosomal Recessive 9 (DFNB9)". Treatment of DFNB9 and other similar forms of hearing loss currently involves the use of cochlear implants for severe or profound hearing loss, and hearing aids for milder forms of hearing loss. There remains a need for alternative forms of treatment that do not rely or rely less on electronic devices to restore hearing. Summary of the Invention

[0003] Provided herein are compositions and methods for expressing otoferlin, for example in cells or subjects.As described herein, it has been found that delivery of OTOF cDNA to OTOF knockout mice via dual adeno-associated virus (AAV) systems containing different portions of OTOF cDNA was capable of rescuing the hearing of the mice to near wild-type levels.

[0004] In some aspects, the disclosure relates to a method of increasing expression of otoferlin in a cell, the method comprising: contacting a cell with a first AAV particle comprising a first polynucleotide; and contacting the cell with a second AAV particle comprising a second polynucleotide, wherein the first polynucleotide comprises an inverted terminal repeat sequence flanked by an expression cassette containing, from 5' to 3': (a) a promoter, (b) a partial coding sequence encoding an N-terminal portion of an otoferlin polypeptide, (c) a splice donor site, and (d) a first region of homology that contains a sequence homologous to a sequence in the second polynucleotide, and the second polynucleotide comprises an inverted terminal repeat sequence flanked by an expression cassette containing, from 5' to 3': (a) a second region of homology that contains a sequence homologous to a sequence in the first polynucleotide, (b) a splice acceptor site, (c) a partial coding sequence encoding a C-terminal portion of an otoferlin polypeptide, and (d) a polyadenylation (pA) signal sequence.

[0005] In some embodiments, the region of homology in the first and second polynucleotides is between 50-500 nucleotides. In some embodiments, the region of homology in the first and second polynucleotides is between 50-300 nucleotides. In some embodiments, the region of homology comprises the nucleotide sequence of SEQ ID NO:3. In some embodiments, the promoter is a chimeric CMV beta actin (smcBA) promoter. In some embodiments, the promoter comprises the sequence of SEQ ID NO:4. In some embodiments, the otoferlin polypeptide comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6. In some embodiments, the splice donor site comprises the sequence of SEQ ID NO:7. In some embodiments, the splice acceptor site comprises the sequence of SEQ ID NO:8. In some embodiments, the inverted terminal repeat is an AAV2 inverted terminal repeat. In some embodiments, the first and second AAV particles are AAV2 serotype particles. In some embodiments, the cell is ex vivo. In some embodiments, the cell is in vivo. In some embodiments, the cell is in a mammalian subject. In some embodiments, the subject has hearing loss, autosomal recessive 9 (DFNB9).

[0006] In another aspect, the disclosure provides a composition comprising: a first AAV particle comprising a first polynucleotide; and a second AAV particle comprising a second polynucleotide, wherein the first polynucleotide comprises an inverted terminal repeat sequence adjacent to an expression cassette containing, from 5' to 3': (a) a promoter, (b) a partial coding sequence encoding an N-terminal portion of an otoferlin polypeptide, (c) a splice donor site, and (d) a first region of homology that contains a sequence homologous to a sequence in the second polynucleotide, and the second polynucleotide comprises an inverted terminal repeat sequence adjacent to an expression cassette containing, from 5' to 3': (a) a second region of homology that contains a sequence homologous to a sequence in the first polynucleotide, (b) a splice acceptor site, (c) a partial coding sequence encoding a C-terminal portion of an otoferlin polypeptide, and (d) a polyadenylation (pA) signal sequence.

[0007] In some embodiments, the region of homology in the first and second polynucleotides is between 50-500 nucleotides. In some embodiments, the region of homology in the first and second polynucleotides is between 50-300 nucleotides. In some embodiments, the region of homology comprises the nucleotide sequence of SEQ ID NO:3. In some embodiments, the promoter is a chimeric CMV beta actin (smcBA) promoter. In some embodiments, the promoter comprises the sequence of SEQ ID NO:4. In some embodiments, the otoferlin polypeptide comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6. In some embodiments, the splice donor site comprises the sequence of SEQ ID NO:7. In some embodiments, the splice acceptor site comprises the sequence of SEQ ID NO:8. In some embodiments, the inverted terminal repeat is an AAV2 inverted terminal repeat. In some embodiments, the first and second AAV particles are AAV2 serotype particles. In some embodiments, the composition further comprises a pharma- ceutically acceptable carrier.

[0008] In still other aspects, the disclosure provides kits comprising a composition as described herein, or comprising a first AAV particle as described herein and a second AAV particle as described herein. These and other aspects are described in greater detail herein.

[0009] BRIEF DESCRIPTION OF THE DRAWINGS The following drawings form part of the specification and are included to further demonstrate certain aspects of the present disclosure that may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. [Brief description of the drawings]

[0010] [Figure 1A]FIG. 1A is a map of the plasmid, which contains the AAV2 inverted terminal repeats (TR) flanked by the CMV enhancer, the chicken beta-actin promoter, a 5' section of mouse otoferlin cDNA (otoferlin NT), a splice donor sequence (APSD), and homologous sequences for recombination (APhead). [Figure 1B] FIG. 1B is a map of the plasmid, which contains the AAV2 inverted terminal repeats (TR) flanked by homologous sequences for recombination (APhead), a splice acceptor sequence (APSA), a 3' section of mouse otoferlin cDNA (otoferlinCT), and a bovine growth hormone polyadenylation signal (bGH polyA). [Diagram 2] FIG. 2 is a schematic diagram of the two expression cassettes in the plasmids in FIGS. 1A and 1B.

[0011] [Figure 3A-1] FIG. 3A shows the annotated sequence of the expression cassette, including the inverted terminal repeats (TR), for the plasmid in FIG. 1A. [Figure 3A-2] FIG. 3A shows the annotated sequence of the expression cassette, including the inverted terminal repeats (TR), for the plasmid in FIG. 1A. [Figure 3A-3] FIG. 3A shows the annotated sequence of the expression cassette, including the inverted terminal repeats (TR), for the plasmid in FIG. 1A. [Figure 3B-1] FIG. 3B shows the annotated sequence of the expression cassette, including the inverted terminal repeats (TR), for the plasmid in FIG. 1B. [Figure 3B-2] FIG. 3B shows the annotated sequence of the expression cassette, including the inverted terminal repeats (TR), for the plasmid in FIG. 1B. [Figure 3B-3] FIG. 3B shows the annotated sequence of the expression cassette, including the inverted terminal repeats (TR), for the plasmid in FIG. 1B.

[0012] [Figure 4] FIG. 4 is a series of photographs showing expression of OTOF protein in HEK 293 cells treated with AAV2-OTOF-NT (AAV-NT), or AAV2-OTOF-NT and AAV2-OTOF-CT (AAV2-NT+CT). [Diagram 5] FIG. 5 is a series of photographs showing GFP expression in surface preparations of the cochlea organ of Corti from wild-type mice treated with AAV2-GFP. [Figure 6A-6B] Figures 6A-D are a series of photographs and graphs showing OTOF expression in the cochlea of ​​P1-P3 mice. Figure 6A shows OTOF protein expression in the mid-turn. Figure 6B shows OTOF protein expression in the apex. [Figure 6C-6D] Figure 6C shows the difference in OTOF expression in the base, midturn and apex in wild-type mice (WT, n=6) and OTOF knockout mice treated with AAV2-OTOF-NT and AAV2-OTOF-CT (Res. KO NT+CT, n=6). The left bar in each pair of bars is WT, and the right bar in each pair of bars is Res. KO NT+CT. Figure 6D shows RT-PCR of OTOF mRNA in wild-type (WT), OTOF knockout mice (KO), and OTOF knockout mice treated with AAV2-OTOF-NT and AAV2-OTOF-CT (Res. KO).

[0013] [Figure 7A] Figures 7A-D show hearing assessment in mice. Figure 7A is a trace of auditory brainstem response (ABR) patterns induced by auditory stimulation in wild-type mice (WT), OTOF knockout mice either untreated (KO / KO NT) or treated with AAV2-OTOF-NT and AAV2-OTOF-CT (rescued KO). [Figure 7B]Figure 7B shows auditory brainstem response (ABR) thresholds in wild-type mice (WT), untreated otoferlin knockout mice (KO), otoferlin knockout mice treated with AAV2-OTOF-NT and AAV2-OTOF-CT (Res KO NT+CT), and otoferlin knockout mice treated with AAV2-OTOF-NT (KO +NT). [Figure 7C] Figure 7C shows the time course of hearing recovery in wild-type mice (WT), untreated OTOF knockout mice (KO), otoferlin knockout mice treated with AAV2-OTOF-NT and AAV2-OTOF-CT (rescued KO NT+CT), and otoferlin knockout mice treated with AAV2-OTOF-NT (KONT). [Figure 7D] Figure 7D shows click ABR thresholds in wild-type mice (WT), untreated otoferlin knockout mice (KO), otoferlin knockout mice treated with AAV2-OTOF-NT and AAV2-OTOF-CT (Res. KO (NT+CT)), and otoferlin knockout mice treated with AAV2-OTOF-NT (KO+NT).

[0014] [Figure 8A-8B] Figures 8A and B show otoferlin protein expression in OTOF-rescued KO mouse inner hair cells. Figure 8A shows OTOF protein expression in mice treated with AAV2-OTOF-NT and AAV2-OTOF-CT at P12 and older. Figure 8B shows the percentage of inner hair cells expressing OTOF in wild-type mice (WT, n=5) and OTOF knockout mice (rescued KO, n=5) treated with AAV2-OTOF-NT and AAV2-OTOF-CT. The left bar in each pair of bars is WT, and the right bar in each pair of bars is rescued KO. [Figure 9A-9B]Figures 9A and 9B are a series of graphs showing hearing assessment. Figure 9A shows the ABR threshold values ​​in wild-type mice (WT), OTOF knockout mice (KO), and OTOF knockout mice (rescued KO) treated with AAV2-OTOF-NT and AAV2-OTOF-CT. Figure 9B shows the hearing life span in WT, KO and rescued KO mice. [Figure 10] FIG. 10 is a map of the plasmid, which contains the AAV2 inverted terminal repeats (TR) flanked by the CMV enhancer, the chicken beta actin promoter, a 5' section of human otoferlin cDNA (otoferlin NT), a splice donor sequence (APSD), and homologous sequences for recombination (APhead). [Figure 11] FIG. 11 is a map of the plasmid, which contains the AAV2 inverted terminal repeats (TR) flanked by homologous sequences for recombination (APhead), a splice acceptor sequence (APSA), a 3' section of human otoferlin cDNA encoding an isoform of otoferlin 1 (otoferlinCT), and a bovine growth hormone polyadenylation signal (bGH polyA).

[0015] [Figure 12] FIG. 12 is a map of the plasmid, which contains the AAV2 inverted terminal repeats (TR) flanked by homologous sequences for recombination (APhead), a splice acceptor sequence (APSA), a 3' section of mouse otoferlin cDNA encoding an isoform of otoferlin 5 (otoferlinCT), and a bovine growth hormone polyadenylation signal (bGH polyA). [Figure 13-1] FIG. 13 shows the annotated sequence of the human OTOF N-terminal expression cassette, including the inverted terminal repeats (TR), for the plasmid in FIG. [Figure 13-2] FIG. 13 shows the annotated sequence of the human OTOF N-terminal expression cassette, including the inverted terminal repeats (TR), for the plasmid in FIG. [Figure 13-3]FIG. 13 shows the annotated sequence of the human OTOF N-terminal expression cassette, including the inverted terminal repeats (TR), for the plasmid in FIG.

[0016] [Figure 14-1] FIG. 14 shows the annotated sequence of the human OTOF C-terminal expression cassette for isoform 1, including the inverted terminal repeats (TR), for the plasmid in FIG. [Figure 14-2] FIG. 14 shows the annotated sequence of the human OTOF C-terminal expression cassette for isoform 1, including the inverted terminal repeats (TR), for the plasmid in FIG. [Figure 14-3] FIG. 14 shows the annotated sequence of the human OTOF C-terminal expression cassette for isoform 1, including the inverted terminal repeats (TR), for the plasmid in FIG. [Figure 15-1] FIG. 15 shows the annotated sequence of the human OTOF C-terminal expression cassette for isoform 5, including the inverted terminal repeats (TR), for the plasmid in FIG. [Figure 15-2] FIG. 15 shows the annotated sequence of the human OTOF C-terminal expression cassette for isoform 5, including the inverted terminal repeats (TR), for the plasmid in FIG. [Figure 15-3] FIG. 15 shows the annotated sequence of the human OTOF C-terminal expression cassette for isoform 5, including the inverted terminal repeats (TR), for the plasmid in FIG. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0017] Detailed Description of the Invention As described herein, it has been found that hearing in otoferlin knockout mice can be restored by treating the mice with two separate AAV particles, one containing the 5' portion of OTOF cDNA and one containing the 3' portion of OTOF cDNA, each containing a region of homology to promote homologous recombination between the 5' and 3' portions in vivo. The region of homology is flanked by a splice donor sequence 5' within the 5' portion of OTOF cDNA and a splice acceptor sequence 3' within the 3' portion of OTOF cDNA. Thus, compositions and methods are provided for increasing the expression of otoferlin.

[0018] Example Definitions Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described herein. For purposes of the present invention, the following terms are defined below:

[0019] As used herein, the terms "nucleic acid" and "polynucleotide sequence" refer to deoxyribonucleotide or ribonucleotide polymers in either single- or double-stranded form, and, unless otherwise limited, encompass known analogues of natural nucleotides that can function in a manner similar to the naturally occurring nucleotides.

[0020] The terms "substantially corresponding to", "substantially homologous" or "substantially identical" as used herein refer to the characteristic of a nucleic acid or amino acid sequence that a selected nucleic acid or amino acid sequence has at least about 70 or about 75 percent sequence identity when compared to the sequence of a selected reference nucleic acid or amino acid sequence. More typically, the selected sequence and the reference sequence have at least about 76, 77, 78, 79, 80, 81, 82, 83, 84 or even 85 percent sequence identity, and more preferably at least about 86, 87, 88, 89, 90, 91, 92, 93, 94 or 95 percent sequence identity. Even more preferably, highly homologous sequences often share greater than at least about 96, 97, 98 or 99 percent sequence identity between the selected sequence and the reference sequence to which it is compared.

[0021] The percentage of sequence identity may be calculated over the entire length of the sequences being compared, or by excluding small deletions or deletions that total less than about 25 percent or so of the selected reference sequence. The reference sequence may be a subset of a larger sequence, such as a portion of a gene or flanking sequence, or a repeated portion of a chromosome. However, in the case of sequence homology between two or more polynucleotide sequences, the reference sequence typically comprises at least about 18-25 nucleotides, more typically 26-35 nucleotides, and even more typically at least about 40, 50, 60, 70, 80, 90, or even 100 nucleotides.

[0022] When highly homologous fragments are desired, the degree of percent identity between the two sequences can be at least about 80%, preferably at least about 85%, and more preferably about 90% or 95% or higher, as readily determined by one or more sequence comparison algorithms well known to those of skill in the art, such as, by way of example, the FASTA program analysis described by Pearson and Lipman.

[0023] Polynucleotides In some aspects, polynucleotides are provided for delivering a portion of the coding sequence of the OTOF gene that encodes the otoferlin protein to cells. In some embodiments, the coding sequence is derived from the human OTOF gene (see, for example, NCBI gene ID: 9381 and cDNA sequences NM_001287489.1, NM_004802.3, NM_194248.2, NM_194322.2, and NM_194323.2). In some embodiments, the coding sequence is derived from the mouse OTOF gene (see, for example, NCBI gene ID 83762 and cDNA sequences NM_001100395.1, NM_001286421.1, NM_001313767.1, and NM_031875.2). In some embodiments, a first and a second polynucleotide are provided. It should be understood that "first," "second," "third," etc. are not meant to imply a particular order or importance unless expressly stated otherwise.

[0024] In some embodiments, the first polynucleotide comprises an inverted terminal repeat sequence flanking an expression cassette that contains, from 5' to 3', one or more of: (a) a promoter, (b) a partial coding sequence encoding an N-terminal portion of an otoferlin polypeptide, (c) a splice donor site, and (d) a first region of homology that contains a sequence homologous to a sequence in a second polynucleotide. In some embodiments, the first polynucleotide comprises at least two, at least three, or all four of (a), (b), (c), and (d).

[0025] In some embodiments, the second polynucleotide comprises an inverted terminal repeat sequence flanking an expression cassette that contains, from 5' to 3', one or more of: (a) a second region of homology that contains a sequence homologous to a sequence in the first polynucleotide, (b) a splice acceptor site, (c) a partial coding sequence encoding a C-terminal portion of an otoferlin polypeptide, and (d) a polyadenylation (pA) signal sequence. In some embodiments, the second polynucleotide comprises at least two, at least three, or all four of (a), (b), (c), and (d).

[0026] The partial coding sequences contained within the polynucleotides described herein can be designed such that upon delivery of the polynucleotide, the partial coding sequences are joined together, for example through homologous recombination, and form a complete coding sequence that encodes an otoferlin polypeptide.

[0027] In some embodiments, the polynucleotide is a plasmid (e.g., a circular nucleic acid that includes one or more of an origin of replication, a selectable marker, and a reporter gene). In some embodiments, the polynucleotides described herein, such as plasmids, may also contain a marker or reporter gene, e.g., LacZ or a fluorescent protein, and an origin of replication. In some embodiments, the plasmid is transfected into a producer cell that produces AAV particles that contain the expression cassette contained within the plasmid.

[0028] In some embodiments, the polynucleotide is a nucleic acid vector, such as a recombinant adeno-associated virus (AAV) vector. Exemplary AAV nucleic acid vectors that are useful according to the present disclosure include single-stranded (ss) or self-complementary (sc) AAV nucleic acid vectors.

[0029] In some embodiments, the recombinant AAV particle comprises a polynucleotide, such as a single-stranded (ss) or self-complementary (sc) AAV nucleic acid vector.In some embodiments, the polynucleotide comprises an expression construct as described herein, and an inverted terminal repeat (ITR) sequence (e.g., a wild-type ITR sequence or an artificially created ITR sequence) flanking the expression construct.In some embodiments, the polynucleotide is encapsidated by a viral capsid.

[0030] Thus, in some embodiments, the AAV particle comprises a viral capsid and a polynucleotide as described herein that is encapsidated by the viral capsid. In some embodiments, the viral capsid comprises 60 capsid protein subunits, including VP1, VP2 and VP3. In some embodiments, the VP1, VP2 and VP3 subunits are present in the capsid at a ratio of approximately 1:1:10, respectively.

[0031] In some embodiments, the polynucleotides (e.g., the first and second polynucleotides) as described herein comprise regions of homology, e.g., to promote homologous recombination between the polynucleotides once delivered to a cell (see, e.g., Ghosh et al. Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences. Hum Gene Ther. 2011 Jan;22(1):77-83). In some embodiments, the first region of homology and the second region of homology have a threshold level of sequence identity with each other to promote homologous recombination. In some embodiments, the first region of homology has at least 75%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity with the second region of homology.

[0032] Unless otherwise specified, the percent sequence identity and / or similarity of two sequences used herein can be determined using the algorithm of Karlin and Altschul (1990) as modified as in Karlin and Altschul (1993). Such algorithms have been incorporated into the NBLAST and XBLAST programs of Altschul et al. (1990). BLAST searches can be performed with the NBLAST program, score=100, wordlength=12, to obtain sequences with a desired percent sequence identity. To obtain gapped alignments for comparison purposes, Gapped BLAST can be used as described (Altschul et al., 1997). When using BLAST and Gapped BLAST, the default parameters of the respective programs (NBLAST and XBLAST) can be used according to published methods. In some embodiments, each region of homology is independently between 50-500, 50-400, 50-300, 100-500, 100-400, 100-300, 200-500, 200-400, or 200-300 nucleotides. In some embodiments, the regions of homology are identical, and each region of homology is between 50-500, 50-400, 50-300, 100-500, 100-400, 100-300, 200-500, 200-400, or 200-300 nucleotides.

[0033] In some embodiments, the region homology is [ka] The sequence may be at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to

[0034] In some embodiments, the polynucleotides described herein may include one or more regulatory elements. One skilled in the art can select regulatory elements for use in an appropriate host cell, e.g., a mammalian or human host cell. Regulatory elements are, for example, promoters, transcription termination sequences, translation termination sequences, enhancers, and polyadenylation elements. The polynucleotides described herein may include a promoter sequence operably linked to a nucleotide sequence encoding a desired polypeptide, such as otoferlin. Promoters contemplated for use in the subject invention include, but are not limited to, cytomegalovirus (CMV) promoter, SV40 promoter, Rous sarcoma virus (RSV) promoter, chimeric CMV / chicken β-actin promoter (CBA) and truncated CBA (smCBA) (see, for example, Haire et al. 2006 and U.S. Patent No. 8,298,818, which are specifically incorporated herein in their entirety by express reference thereto). In some embodiments, the promoter is a truncated chimeric CMV β-actin (smcBA) promoter.

[0035] In some embodiments, the promoter comprises the nucleotide sequence [ka] The sequence may be at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to

[0036] In some embodiments, the polynucleotide as described herein comprises a partial coding sequence encoding an N-terminal or C-terminal portion of an otoferlin polypeptide, where the partial coding sequence can be spliced ​​or otherwise combined together in vivo to encode an otoferlin polypeptide. In some embodiments, the otoferlin polypeptide is a human otoferlin polypeptide. In some embodiments, the otoferlin polypeptide is a long isoform of a human otoferlin polypeptide (see, for example, Yasunaga et al. OTOF Encodes Multiple Long and Short Isoforms: Genetic Evidence That the Long Ones Underlie Recessive Deafness DFNB9. Am. J. Hum. Genet. 67:591-600, 2000).

[0037] In some embodiments, the otoferlin polypeptide comprises a sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100 identical to one or both of the following amino acid sequences:

[0038] Human OTOF isoform 1 - Genbank number AF183185.1 [ka] [ka]

[0039] Human OTOF isoform 5 - Genbank number NP_001274418 [ka] [ka]

[0040] In some embodiments, the otoferlin polypeptide is a mouse otoferlin polypeptide. In some embodiments, the otoferlin polypeptide comprises a sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100 identical to the following amino acid sequence:

[0041] Mouse OTOF isoform 1 - Genbank number NP_001093865.1 [ka] [ka]

[0042] In some embodiments, the polynucleotides described herein comprise a splice donor or splice acceptor site. In some embodiments, the splice donor and / or splice acceptor site contain a splice consensus sequence. In some embodiments, the splice donor and / or splice acceptor site contain the sequence of a splice consensus sequence derived from alkaline phosphatase.

[0043] In some embodiments, the splice donor site is [ka] The sequence may be at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to

[0044] In some embodiments, the splice acceptor site is selected from the group consisting of the nucleotide sequence [ka] The sequence may be at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to

[0045] In some embodiments, the oligonucleotides described herein comprise ITR sequences.The ITR sequences of the polynucleotides described herein can be derived from any AAV serotype (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) or can be derived from more than one serotype.In some embodiments of the polynucleotides provided herein, the ITR sequences are derived from AAV2. ITR sequences, and plasmids containing ITR sequences, are known in the art and commercially available (e.g., products and services available from Vector Biolabs, Philadelphia, PA; Cellbiolabs, San Diego, CA; Agilent Technologies, Santa Clara, Ca; and Addgene, Cambridge, MA; and "Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein." Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ. Proc Natl Acad Sci US A. 1996 Nov 26;93(24):14082-7; and Curtis A. Machida. "Methods in Molecular Medicine TM." "Viral Vectors for Gene Therapy Methods and Protocols." 10.1385 / 1-59259-304-6:201 (C) Humana Press Inc. 2003. Chapter 10, "Targeted Integration by Adeno-Associated Virus." Matthew D. Weitzman, Samuel M. Young Jr., Toni Cathomen and Richard Jude Samulski; see U.S. Patent Nos. 5,139,941 and 5,962,313, all of which are incorporated herein by reference.).

[0046] An exemplary AAV2 ITR sequence for adjacent the 5' end of the expression construct is the sequence: [ka] Includes. An exemplary AAV2 ITR sequence for adjacent the 3' end of the expression construct is the sequence: [ka] Includes.

[0047] In some embodiments, the polynucleotides described herein may further include one or more transcription termination sequences, one or more translation termination sequences, one or more signal peptide sequences, one or more internal ribosome entry sites (IRES), and / or one or more enhancer elements, or any combination thereof. Transcription termination regions can typically be obtained from the 3' untranslated region of eukaryotic or viral gene sequences. Transcription termination sequences can be located downstream of the coding sequence to allow efficient termination. Signal peptide sequences are amino-terminal peptide sequences that code for information responsible for the location of an operably linked polypeptide to one or more post-translational cellular destinations, including, for example, specific organelle compartments or sites of protein synthesis and / or activity, and even the extracellular environment. In some embodiments, the polynucleotides as described herein include a bovine growth hormone polyadenylation signal.

[0048] In some embodiments, an expression construct contained within a polynucleotide described herein is no greater than 5 kilobases, no greater than 4 kilobases, or no greater than 3 kilobases in size, hi some embodiments, an expression construct is between 4 and 5 kilobases in size.

[0049] In some embodiments, the polynucleotides described herein are contained within one or more recombinant AAV particles (e.g., a first and a second AAV particle). The rAAV particles can be of any AAV serotype (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10), including any derivative (including non-naturally occurring variants of a serotype) or pseudotype. Non-limiting examples of derivatives and pseudotypes include AAV2-AAV3 hybrid, AAVrh.10, AAVhu.14, AAV3a / 3b, AAVrh32.33, AAV-HSC15, AAV-HSC17, AAVhu.37, AAVrh.8, CHt-P6, AAV2.5, AAV6.2, AAV2i8, AAV-HSC15 / 17, AAVM41, AAV9.45, AAV6(Y445F / Y731F), AAV2.5T, AAV-HAE1 / 2, AAV clone 32 / 83, AAVShH10, AAV2 (Y→F), AAV8 (Y733F), AAV2.15, AAV2.4, AAVM41, and AAVr3.45. Such AAV serotypes and derivatives / pseudotypes, and methods for producing such derivatives / pseudotypes, are known in the art (see, e.g., Mol Ther. 2012 Apr;20(4):699-708. doi: 10.1038 / mt.2011.287. Epub 2012 Jan 24. "The AAV vector toolkit: poised at the clinical crossroads." Asokan A1, Schaffer DV, Samulski RJ.). In some embodiments, the first and second AAV particles are AAV2 serotype particles.

[0050] Methods for producing AAV particles and polynucleotides are known in the art and commercially available (see, e.g., Zolotukhin et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158-167; and U.S. Patent Publication Nos. US20070015238 and US20120322861, which are incorporated herein by reference; and plasmids and kits available from ATCC and Cell Biolabs, Inc.). For example, polynucleotides (e.g., as plasmids) may be combined with one or more helper plasmids, e.g., containing rep genes (e.g., encoding Rep78, Rep68, Rep52, and Rep40) and cap genes (encoding VP1, VP2, and VP3), and transfected into a producer cell line to allow AAV particles to be packaged and subsequently purified.

[0051] In some embodiments, the one or more helper plasmids include a first helper plasmid that contains the rep and cap genes, and a second helper plasmid that contains other genes that are helpful in AAV production, such as the E1a, E1b, E4, E2a, and VA genes, In some embodiments, the rep gene is from AAV2. Helper plasmids and methods for making such plasmids are known in the art and commercially available (e.g., pDM, pDG, pDP1rs, pDP2rs, pDP3rs, pDP4rs, pDP5rs, pDP6rs, pDG(R484E / R585E), and pDP8.ape plasmids from PlasmidFactory, Bielefeld, Germany; Vector Biolabs, Philadelphia, PA; Cellbiolabs, San Diego, CA; Agilent Technologies, Santa Clara, Ca; and other products and services available from Addgene, Cambridge, MA; pxx6; Grimm et al. (1998), Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors, Human Gene Therapy, Vol. 9, 2745-2760; Kern, A. et al. (2003), Identification of a Heparin-Binding Motif on Adeno-Associated Virus Type 2 Capsids, Journal of Virology, Vol. 77, 11072-11081.;Grimm et al. (2003), Helper Virus-Free, Optically Controllable, and Two-Plasmid-Based Production of Adeno-associated Virus Vectors of Serotypes 1 to 6, Molecular Therapy,Vol.7, 839-850;Kronenberg et al. (2005), A Conformational Change in the Adeno-Associated Virus Type 2 Capsid Leads to the Exposure of Hidden VP1 N Termini, Journal of Virology, Vol. 79, 5296-5303;and Moullier, P. and Snyder, RO (2008), International efforts for recombinant adenoassociated viral vector reference standards, Molecular Therapy, Vol. 16, 1185-1188).

[0052] A non-limiting, exemplary AAV particle production method is described below. One or more helper plasmids containing the rep and cap ORFs for the desired AAV serotype and the adenovirus VA, E2A (DBP) and E4 genes under the transcriptional control of the native promoter are produced or obtained. HEK293 cells (available from ATCC®) are transfected with the helper plasmid(s) and the plasmid containing the polynucleotide described herein via CaPO4-mediated transfection, lipids or polymer molecules such as polyethyleneimine (PEI). Alternatively, in another non-limiting example, an Sf9-based producer stable cell line is infected with a single recombinant baculovirus containing the polynucleotide. As a further non-limiting alternative, in another example, HEK293 or BHK cell line is infected with HSV containing polynucleotide and optionally with one or more helper HSV containing rep and cap ORFs as described herein and adenovirus VA, E2A (DBP) and E4 genes under the transcriptional control of native promoter.HEK293, BHK or Sf9 cells are then incubated for at least 60 hours to allow AAV particle production.AAV particles can then be purified using any method known in the art or described herein, for example by iodixanol step gradient, CsCl gradient, chromatography or polyethylene glycol (PEG) precipitation.

[0053] The present disclosure also contemplates a host cell comprising at least one of the disclosed AAV particles or polynucleotides. Such host cells include mammalian host cells, preferably human host cells, and may be either isolated or in cell or tissue culture. In the case of genetically modified animal models (e.g., mice), the transformed host cell may be within the non-human animal itself.

[0054] Methods and Subjects In some aspects, a method for increasing the expression of otoferlin in a cell is provided. In some embodiments, the method comprises contacting the cell with a first AAV particle as described herein, comprising a first polynucleotide as described herein; and contacting the cell with a second AAV particle as described herein, comprising a second polynucleotide as described herein. In some embodiments, the cell is a mammalian cell, such as a mouse or human cell. In some embodiments, the cell is ex vivo. In some embodiments, the cell is in vivo. In some embodiments, the cell is an ear cell (e.g., a human ear cell). In some embodiments, the cell is an inner ear cell (e.g., a human inner ear cell). In some embodiments, the cell is in a subject (e.g., a mammalian subject, such as a human subject).

[0055] Other aspects of the present disclosure relate to the treatment of diseases or conditions caused by the reduction or absence of otoferlin expression or activity. In some embodiments, the method comprises administering to a subject a therapeutically effective amount of a first AAV particle comprising a first polynucleotide as described herein and a second AAV particle comprising a second polynucleotide as described herein. In some embodiments, the subject is a human subject, and the subject has hearing loss, autosomal recessive 9 (DFNB9). In some embodiments, the subject is a human subject with impaired vestibular function or vestibular disorder (see, for example, Dulon et al. Otoferlin is Critical for a Highly Sensitive and Linear Calcium Dependent Exocytosis at Vestibular Hair Cell Ribbon Synapses. J Neurosci. 2009; 29(34): 10474-10487).

[0056] "Treating" a disease, as the term is used herein, means reducing the frequency or severity of at least one sign or symptom of a disease or disorder experienced by a subject. The compositions described above or elsewhere herein are typically administered to a subject in an effective amount, i.e., an amount capable of producing a desired result. The desired result depends on the active agent administered. For example, an effective amount of AAV particles can be the amount of particles capable of transferring an expression construct to a host organ, tissue, or cell. A therapeutically acceptable amount can be an amount capable of treating a disease, for example, DFNB9. As is well known in the medical and veterinary fields, the dosage for a subject depends on many factors, including the subject's size, body surface area, age, the specific composition administered, the active ingredient(s) in the composition, the time and route of administration, general health, and other drugs administered simultaneously.

[0057] AAV particles or polynucleotides can be delivered in the form of a composition, such as a composition that comprises an active ingredient, such as the AAV particles described herein, and a pharma- ceutically acceptable carrier as described herein.AAV particles or polynucleotides can be prepared in various compositions, and can also be formulated with a suitable pharmaceutical vehicle for administration to human or animal subjects.In some embodiments, when the first and second AAV particles are utilized, the first and second AAV particles can be contained in the same composition, or can be contained in different compositions, and can be administered together or separately.

[0058] In some embodiments, the AAV particles administered to the subject are 6 ~10 14 particles / ml or 10 3 ~10 15 In compositions having concentrations ranging on the order of particles / ml, or, for example, about 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11, 10 12 , 10 13 , or 10 14 In one embodiment, the amount of the 1000 ng / ml ... 13 In some embodiments, the number of AAV particles administered to a subject is greater than 10 particles / ml. 6 ~10 14 Vector genomes (vgs) / ml or 10 3 ~10 15 vgs / ml, or, for example, on the order of about 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , or 10 14 In one embodiment, the concentration is 10 to 200 mg / mL, and may be any value between any of the ranges, such as 10 vgs / ml. 13 More than vgs / ml of AAV particles are administered. The AAV particles can be administered as a single dose or can be divided into two or more administrations as may be required to achieve treatment of the particular disease or disorder being treated. In some embodiments, 0.0001 ml to 10 mls are delivered to the subject.

[0059] In some embodiments, the number of AAV particles administered to a subject is 10 6 ~10 14 vg / kg, or, for example, on the order of about 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , or 10 14The amount of AAV administered may be any value between any range, such as vgs / kg. In some embodiments, when a first AAV particle comprising a first polynucleotide as described herein and a second AAV particle comprising a second polynucleotide as described herein are administered, the amount administered is the same for both particles. In some embodiments, when a first AAV particle comprising a first polynucleotide as described herein and a second AAV particle comprising a second polynucleotide as described herein are administered, the amount administered is different for each particle.

[0060] If desired, AAV particles may be administered in combination with other agents or treatments, such as, for example, proteins or polypeptides or various pharmacologic active agents (including systemic or local administration of one or more therapeutic polypeptides, biologically active fragments, or variants thereof). In fact, there is virtually no limit to the other components that may be included, provided that the additional agents do not cause significant adverse effects upon contact with target cells or host tissues. Thus, AAV particles may be delivered with various other agents or treatments as required in a particular case. In some embodiments, the treatment of AAV particles may be accompanied by the use of a hearing aid.

[0061] In some circumstances, it is preferred to deliver AAV particles in a suitably formulated pharmaceutical composition as described herein to one or more cells, tissues, or organs, either subcutaneously, parenterally, intravenously, intramuscularly, intraperitoneally, by oral or nasal inhalation, or by direct injection. In some embodiments, administration is by a suitable route for systemic delivery, such as by intravenous injection or infusion. In some embodiments, administration is to the ear, for example, via intracochlear administration. Pharmaceutical forms of AAV particle compositions suitable for injectable use include sterile aqueous solutions or dispersions. In some embodiments, the forms are sterile and fluid to the extent that easy injectability exists. In some embodiments, the forms are stable under the conditions of manufacture and storage, and are preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be, for example, a solvent or dispersion medium containing water, saline, ethanol, a polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and / or vegetable oils. Proper fluidity can be maintained by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0062] For administration of injectable aqueous solutions, for example, the solution may be suitably buffered if necessary, and the liquid diluent may first be made isotonic with sufficient saline or glucose. These particular aqueous solutions are particularly suitable for intravenous, intramuscular, intravitreal, subretinal, subcutaneous, and intranasal administration. In this regard, in light of the present disclosure, the skilled artisan will know the sterile aqueous media that may be employed. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and added to 1000 ml of subcutaneous injection fluid, or injected at the proposed injection site (see, for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Depending on the condition of the subject being treated, some variation in dosage will necessarily occur. In any event, the person responsible for administration will determine the appropriate dose for the individual subject. Moreover, for human administration, preparations must meet sterility, pyrogenicity, and general safety and purity standards, as required by, for example, FDA Office of Biosystems Control standards.

[0063] Sterile injectable solution is prepared by incorporating AAV in the required amount in a suitable solvent, optionally with some of the other components listed above, followed by sterilization by filtration or other sterilization techniques.Generally, dispersion is prepared by incorporating various sterilized active ingredients into a sterilized medium that contains a basic dispersion medium and other necessary components listed above.In the case of sterilized powder for preparing sterile injectable solution, the preferred preparation method is vacuum drying and freeze-drying techniques, which obtains powder of active ingredient and any additional desired ingredient from its solution that has been previously sterilized by filtration.

[0064] The amount of AAV particle or polynucleotide composition and the time of administration of such composition are within the knowledge of the person skilled in the art who has the benefit of the present teaching.However, the administration of a therapeutically effective amount of the disclosed composition may be achieved by a single administration, such as a single injection of a sufficient number of infectious particles, to provide therapeutic benefit to the patient undergoing such treatment.Alternatively, in some situations, it may be desirable to provide multiple or continuous administrations of AAV particle composition over a relatively short or long period of time, as can be determined by the physician who supervises the administration of such composition. The compositions may include AAV particles, alone or in combination with one or more additional active ingredients, which can be obtained from natural or recombinant sources or chemically synthesized.

[0065] The toxicity and efficacy of the compositions utilized in the methods of the present disclosure can be determined by standard pharmaceutical procedures, using either cultured cells or experimental animals to determine the LD50 (the dose that is lethal to 50% of the population). The dose ratio between toxicity and efficacy is the therapeutic index, which can be expressed as the ratio LD50 / ED50. Compositions that exhibit large therapeutic indices are preferred. Those that exhibit toxic side effects can also be used, but care must be taken to design a delivery system that minimizes the potential damage from such side effects. The dosage of the compositions as described herein generally falls within a range that includes the ED50 with little or no toxicity. Dosage can vary within this range, depending on the dosage form employed and the route of administration utilized.

[0066] Aspects of the present disclosure relate to methods for use with subjects, such as human or non-human primate subjects.Non-limiting examples of non-human primate subjects include macaques (e.g., cynomolgus or rhesus monkeys), marmosets, tamarins, spider monkeys, night monkeys, vervet monkeys, squirrel monkeys, baboons, gorillas, chimpanzees, and orangutans.In some embodiments, the subject is a human subject.Other exemplary subjects include domesticated animals, such as dogs and cats; livestock animals, such as horses, cows, pigs, sheep, goats, and chickens; and other animals, such as mice, rats, guinea pigs, and hamsters.

[0067] In some embodiments, the subject has or is suspected to have a disease that can be treated with gene therapy. In some embodiments, the subject has or is suspected to have deafness, autosomal recessive 9 (DFNB9). DFNB9 is an autosomal recessive form of deafness that is believed to be caused by a mutation in the OTOF gene that results in a decrease in the expression, function, or both of otoferlin protein. Otoferlin protein has been shown to be important for exocytosis at the auditory ribbon synapse (see, for example, Roux et al. Otoferlin, defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse. (2006) Cell 127(2):277-89). Subjects with DFNB9 can be identified by a skilled physician using, for example, electrophysiological testing of auditory brainstem response (ABR) in combination with genetic testing to identify mutations in the OTOF gene (see, for example, OMIM entries 603681 and 601071).

[0068] In some embodiments, the subject is a human subject with one or more of the following nonsense or missense mutations in the OTOF gene: TYR730TER, GLN829TER, PRO1825ALA, PRO50ARG, LEU1011PRO, ILE515THR, ARG1939GLN, or GLY541SER. In some embodiments, the subject is a human subject with an A to G transition (IVS8-2A-G) at the intron 8 / exon 9 junction, or a G to A transition at position +1, the first intron nucleotide, at the splice donor site of exon 5, or a G to C transversion at the donor splice site of intron 39. In some embodiments, the subject is a human subject with a one base pair deletion (1778G) in exon 16, which leads to a stop codon, and a 6141G-A change, which results in an ARG to GLN substitution in exon 48.

[0069] composition Other aspects of the disclosure relate to compositions comprising the AAV particles or polynucleotides described herein. In some embodiments, the AAV particles described herein are added to a composition, such as a pharmaceutical composition.

[0070] In some embodiments, the composition comprises a pharma- ceutically acceptable carrier.The term "carrier" refers to a diluent, adjuvant, excipient or vehicle with which AAV is administered.Such pharmaceutical carriers can be sterile liquids such as water or oil, including petroleum oil such as mineral oil, vegetable oil such as peanut oil, soybean oil and sesame oil, animal oil, or synthetic oil.Saline solution and aqueous dextrose and glycerol solution can also be employed as liquid carriers. Non-limiting examples of pharma- ceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, saline, syrup, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, polyacrylic acid, lubricants (such as talc, magnesium stearate, and mineral oil), wetting agents, emulsifying agents, suspending agents, preservatives (such as methyl-, -ethyl-, and -propyl-hydroxybenzoates), and pH adjusting agents (such as inorganic and organic acids and bases).

[0071] Other examples of carriers include phosphate buffered saline, HEPES buffered saline, and water for injection, any of which may be optionally combined with one or more of calcium chloride dihydrate, disodium phosphate anhydrous, magnesium chloride hexahydrate, potassium chloride, potassium dihydrogen phosphate, sodium chloride, or sucrose. Examples of other carriers that may be used include saline (e.g., sterile, pyrogen-free saline), saline buffers (e.g., citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohol, ascorbic acid, phospholipids, proteins (e.g., serum albumin), EDTA, sodium chloride, liposomes, mannitol, sorbitol, and glycerol. USP grade carriers and excipients are particularly useful for delivery of AAV particles to human subjects. Such compositions may further optionally comprise liposomes, lipids, lipid complexes, microspheres, microparticles, nanospheres, or nanoparticles, or may be otherwise formulated for administration to a cell, tissue, organ, or the body of a subject in need thereof. Methods for making such compositions are well known and are described, for example, in Remington: The Science and Practice of Pharmacy, 22 nd edition, Pharmaceutical Press, 2012.

[0072] Typically, such compositions will contain at least about 0.1% of a therapeutic agent (e.g., AAV particles) or more, although the percentage of active ingredient(s) may of course vary and may conveniently be between about 1 or 2% and about 70% or 80% or more by weight or volume of the total formulation. Of course, the amount of therapeutic agent(s) (e.g., AAV particles) in each therapeutically useful composition may be prepared in such a way that a suitable dosage is obtained in any given unit dose of compound. Factors such as solubility, bioavailability, biological half-life, route of administration, shelf life of the product, as well as other pharmacological considerations will be contemplated by those skilled in the art of preparing such pharmaceutical formulations, and therefore various dosages and treatment regimes may be desirable.

[0073] In some embodiments, the compositions described herein may be administered to a subject in need thereof, such as a subject with DFNB9. In some embodiments, the methods described herein may include administering one or more compositions comprising AAV particles as described herein to a subject in need thereof. In some embodiments, the subject is a human subject. In some embodiments, the subject has or is suspected of having a disease that can be treated with gene therapy, such as DFNB9. In some embodiments, the subject has been diagnosed with DFNB9.

[0074] kit Another aspect of the present disclosure relates to a kit comprising AAV particles or polynucleotides as described herein in one or more containers. The kit can optionally include a pharmaceutically acceptable carrier and / or diluent. In some embodiments, the kit includes instructions or packaging materials that explain how to administer the AAV particles or polynucleotides contained within the kit to selected cells or recipients. The containers of the kit can be any suitable material (e.g., glass, plastic, metal, etc.) and can be any suitable size, shape, or configuration. In some embodiments, the kit can include one or more ampoules or syringes that contain the AAV particles or polynucleotides in a suitable liquid or solution form. EXAMPLES

[0075] example Rescue of hearing in OTOF knockout mice using an adeno-associated virus gene therapy approach Introduction Otoferlin is an important calcium sensor for neurotransmitter release in the ear (see, for example, Roux 2006). It is expressed mainly in the inner hair cells of the cochlea and in a few other cells of the central nervous system (see, for example, Yasunaga et al. 1999 & 2000). It is a member of the ferlin family of transmembrane proteins that share a common C2 domain also found in synaptotagmins, PKC and PLC.

[0076] Mutations in the human OTOF gene, which encodes human otoferlin, cause a type of nonsyndromic hearing loss called "deafness, autosomal recessive 9 (DFNB9)". OTOF knockout mice have also been shown to have severe hearing loss despite normal inner hair cell development and auditory ribbon synapse formation (see, for example, Roux et al. (2006) Otoferlin, defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse. Cell. 127:277-289). However, Otof - / - Mice lose auditory brainstem responses across all sound frequencies due to a complete abrogation of synaptic exocytosis and, consequently, neurotransmitter release from synaptic vesicles.

[0077] DFNB9 manifests as two phenotypes in humans, a nonsyndromic bilateral hearing loss prior to language acquisition and, less frequently, a temperature-sensitive nonsyndromic auditory neuropathy, which was first discovered in an affected Lebanese family (Chaib et al. 1996) and has since been found in many parts of the world (see, for example, Adato et al. 2000; Rodriguez-Ballesteros et al. 2003; Choi et al. 2009; Matsunaga et al. 2012).

[0078] Current treatments in humans with DFNB9 utilize cochlear implants and hearing aids. In addition, for the temperature-sensitive form of DFNB9, prevention of fever and other conditions that cause elevated body temperature is important. As a proof of concept for using AAV to deliver OTOF as a treatment for DFNB9, applicants aimed to use adeno-associated virus (AAV) as a means to restore expression of OTOF in knockout mice. The mouse OTOF cDNA is 5979 base pairs in length, while most AAVs are unable to package genomes larger than approximately 4.8 kilobases. As a result, a dual vector system was used to deliver the 5' portion of the cDNA and the 3' portion of the cDNA separately as separate AAV constructs so that the full-length cDNA could be reassembled in vivo once delivered.

[0079] method Dual AAV vector constructs The mouse OTOF cDNA was split into two sections, the 5' and 3' sections, and inserted into two AAV ITR-containing plasmids. The sequences of each of the two cassettes in the plasmids are shown below, and maps of each construct are shown in Figures 1 and 2. Annotated versions of the cassettes are shown in Figures 3A and 3B. Each cassette contains a region of homology to promote homologous recombination between the 5' and 3' ends of the cDNA in vivo (see Ghosh et al., 2011). Once recombined in vivo, the full-length cDNA contains a splice donor / splice acceptor pair that causes excision by splicing from the region of homology. The vector was packaged into AAV2 serotype particles using standard plasmid transfection methods as previously described (see Zolotukhin et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158-167). The viral particles were purified by standard methods as previously described (see Zolotukhin et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158-167). The viral particles carrying the 5' portion of the OTOF cDNA are also referred to herein as "AAV2-OTOF-NT". The viral particles carrying the 3' portion of the OTOF cDNA are also referred to herein as "AAV2-OTOF-CT".

[0080] pTR22-smCBA-otoferlinNT-APSD-APhead [ka] [ka] [ka] [ka] [ka]

[0081] pTR22-APhead-APSA-otoferlinCT [ka] [ka] [ka] [ka] [ka]

[0082] Transfection of HEK 293 cells HEK 293 cells were grown on polylysine-coated coverslips in culture medium. 1 μl of each virus was used for each well as follows: control cells without virus, cells with the n-terminal portion of AAV2-OTOF (AAV2-OTOF-NT), cells with the c-terminal portion of AAV2-OTOF (AAV2-OTOF-CT), and cells with both viruses (AAV2-OTOF-NT and AAV2-OTOF-CT). Cells were stained with anti-OTOF antibody and mounted on glass slides.

[0083] OTOF knockout mice The OTOF knockout mice used were generated in a previous study (see Roux et al. (2006) Otoferlin, defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse. Cell. 127:277-289). Briefly, two fragments containing genomic sequences 5' and 3' to exons 14 and 15 of Otof were amplified by PCR. The 5 kb BamHI-XhoI-BssHII and 6 kb BssHII-SfiI-BamHI-NaeI ​​129 / SvPas fragments were inserted into pUC19 (New England BioLabs) that had been previously modified by inserting a BamHI-XhoI-BssHII-SfiI-NaeI-HindIII polylinker. A loxP-hygro-loxP (a gene conferring resistance to hygromycin under the control of the phosphoglycerate kinase gene [Pgk-1] promoter) cassette was inserted into the BssHII site. All constructs were sequenced and the resulting sequences were compared to the 129 / SvPas genomic sequence. 282 CK35 ES cells resistant to hygromycin were screened for homologous recombination and monoinsertion events by Southern blot analysis.

[0084] To generate chimeric animals, two clones were injected into C57BL / 6N blastocysts. Transmission of the mutant Otof allele was detected by PCR in agouti pups. Positive pups in the F1 progeny were mated with Pgk-1-cre mice in a mixed C57BL / 6-129 / SvPas background. F2 animals carrying the allele with the deleted hygromycin cassette (Otof tm1Ugds allele) were selected by PCR using primers 5'-CACTTGCTTTGTCT CATCTCC-3' (SEQ ID NO: 12) and 5'-GTCACTTCTTCTGGGTATTTC-3' (SEQ ID NO: 13), which generated a PCR product of 507 base pairs. Heterozygous animals were then transfected with Otof - / - , Otof + / - , and Otof + / + The mice were interbred to generate knockout mice. Knockout mice were generated in the C57BL / 6-129 / SvPas background as described above. Because this background strain is known to have some age-related hearing loss, the mice were backcrossed to the FVB mouse strain for 10 generations to obtain a homogenous genetic background of FVB without the known age-related hearing loss.

[0085] Delivery of AAV into mice OTOF knockout mice (newborn and older than P10) were injected with 1 microliter of viral particles of each of the two AAV constructs using round window membrane (RWM) injection as previously described (see Akil et al. (2012) Restoration of Hearing in the VGLUT3 Knockout Mouse Using Virally-Mediated Gene Therapy. Neuron. 75(2): 283-293 and Akil et al. (2015) Surgical Method for Virally Mediated Gene Delivery to the Mouse Inner Ear through the Round Window Membrane. J. Vis. Exp. (97), e52187). AAV2-OTOF-NT (6.32 × 10 12 vg / ml) and AAV2-OTOF-CT (4.5 × 10 12 AAV2-OTOF-NT (1.43 × 10 vg / ml) was delivered to P1-3 mice through the RWM. 13 vg / ml) and AAV2-OTOF-CT (3.12 × 10 13 vg / ml) was delivered through the RWM to P≧12 mice. ABR testing was performed 7 days after injection. OTOF protein expression in mice was measured using anti-OTOF antibody to label cells in whole mount cochlea preparations. Reverse transcriptase (RT)-PCR was used to screen for the presence of OTOF mRNA within mouse cochlear tissue. Wild-type mice were also injected with AAV2-GFP using the same technique to evaluate viral delivery to the cochlea with AAV2. Cochleae were whole mounted and stained with anti-GFP antibody.

[0086] Auditory Brainstem Response (ABR) Testing Hearing tests were performed on otoferlin knockout (OTOF KO) mice, rescued OTOF KO mice, and wild-type (WT) littermates as previously described (Akil et al. (2006) Progressive deafness and altered cochlear innervation in knockout mice lacking prosaposin. J. Neurosci. 26:13076-13088 and Akil et al. (2016) Mouse Auditory Brainstem Response Testing. Bio Protoc. 6(6)). Briefly, all hearing tests were performed in a soundproof room. Prior to hearing tests, mice were anesthetized by intraperitoneal injection of a mixture of ketamine hydrochloride (Ketaset, 100 mg / ml) and xylazine hydrochloride (xyla-ject, 10 mg / ml) and boosted with one-fifth of the initial dose, if necessary. Throughout the recordings, body temperature was maintained with a heating pad and monitored with a rectal probe.

[0087] Evoked auditory brainstem response (ABR) thresholds were recorded separately from the scalp of mice. Responses were recorded using subdermal needle electrodes at the vertex, under the pinna of the left ear (reference), and under the contralateral ear (ground). Sound stimuli used included clicks (5 ms duration, 31 Hz) and tone pips (10 ms duration, cos2 shaped, 21 Hz) at 8, 16, and 32 kHz. Measurements were recorded using a TDT BioSig III system (Tucker Davis Technologies). For each stimulus, electroencephalographic (EEG) activity was recorded for 20 ms (at a sampling rate of 25 kHz) and filtered (0.3–3 kHz). For click responses, waveforms from 512 stimuli were averaged. To identify frequency-specific tone burst stimuli (8, 16, and 32 kHz), waveforms from 1000 stimuli were examined. ABR waveforms were recorded at intervals of 5 dB sound pressure level (SPL) below maximum amplitude. Threshold was defined as the lowest stimulus level at which a clear and repeated response peak for wave IV was present by visual inspection. These threshold judgments were confirmed by analysis of stored waveforms. Comparisons between groups of animals were performed using one-way ANOVA with Bonferroni post-hoc tests.

[0088] result Two different AAV plasmid constructs were created to deliver the 5' and 3' halves of mouse OTOF cDNA to the inner ear of OTOF knockout mice (OTOF N-terminal virus and OTOF C-terminal virus). The two constructs were packaged separately into AAV2 particles. The AAV2 particles were then pooled together and used to treat HEK 293 cells or injected into the inner ear of OTOF knockout mice. It was shown that HEK 293 cells expressed otoferlin protein only when transfected with both viruses (Figure 4). No expression of otoferlin protein was observed in untreated cells or in cells transfected with only the OTOF N-term (Figure 4) or OTOF C-term viruses.

[0089] Next, the ability of AAV2 to transduce the mouse cochlea was evaluated using the AAV2-GFP reporter virus. AAV2 was shown to transfect multiple cell types, including inner hair cells (IHCs), outer hair cells (OHCs), pillar cells (Ps), and other indicator cells (SCs) (Figure 5). Thus, AAV2 can effectively transduce the mouse cochlea.

[0090] Mice were then treated with pooled OTOF N-terminal and C-terminal viruses and compared to various controls. Otoferlin protein was found to be expressed upon treatment with both viruses (Figure 6). The greatest number of transfected inner hair cells (IHCs) was observed in the base, with fewer in the mid-turn and apex (Figure 6). IHC counting demonstrated that overall approximately 11% of IHCs were labeled, with significant differences seen between the base (approximately 29%), mid-turn (approximately 8%), and apex (approximately 2%) (Figure 6). Using RT-PCR, it was shown that OTOF mRNA was present in total cochlear extracts and was the same size in both wild-type and OTOF knockout mice treated with both viruses (Figure 6). In contrast, no OTOF mRNA expression was demonstrated in the cochleae of untreated OTOF knockout mice. No product was detected when RT-PCR was performed in the absence of reverse transcriptase.

[0091] Next, hearing tests were performed to determine whether otoferlin expressed by both N- and C-terminal virus delivery had the ability to rescue hearing function. The ABR waveforms from wild-type and OTOF knockout mice treated with both viruses were similar, demonstrating hearing recovery in the rescued KO mice, whereas untreated OTOF knockout mouse controls and OTOF knockout mice transfected with OTOF N-terminal virus alone showed no hearing recovery (Figure 7). At P70, partial hearing recovery (improved ABR thresholds) was seen for clicks and at specific frequencies of 8, 16, and 32 kHz in OTOF knockout mice treated with both viruses, although ABR thresholds at 8 and 16 kHz appeared slightly elevated, still significantly better than untreated OTOF knockout mice (Figure 7). Notably, hearing was maintained for more than 4 months in OTOF knockout mice treated with both viruses (KO NT+CT), although there was some variation in ABR thresholds (Figure 7). Untransfected KO controls and OTOF NT-transfected KOs remained deaf (Fig. 7 ).

[0092] Next, OTOF knockout mice older than P12 were treated with both viruses. Doubly transfected IHCs expressed OTOF, with uniform transfection rates at the base (not shown) and apex (Figure 8). IHC counting demonstrated that overall, approximately 41% of IHCs were labeled, with minor differences between the base (approximately 38%), midturn (approximately 42%), and apex (approximately 47%) (Figure 8).

[0093] At P60, all OTOF knockout mice treated with both viruses demonstrated normal ABR thresholds to click stimuli, although at certain frequencies of 8, 16, and 32 kHz, ABR thresholds appeared to be slightly elevated, but were still significantly better than untreated OTOF knockout mice (Figure 9). The time course of hearing recovery following injection of both viruses into OTOF knockout mice aged P12 and older showed that hearing was maintained for more than 30 weeks in treated mice, and ABR thresholds were restored to WT levels (Figure 9).

[0094] These results demonstrate that the use of more than one AAV construct to deliver different portions of the OTOF cDNA can result in a functional cDNA in vivo. These results also demonstrate that hearing loss can be treated by delivery of the OTOF cDNA using an AAV delivery system.

[0095] Example 2: Human OTOF dual vector construct Provided below are examples of dual vector sequences for expressing human otoferlin protein isoforms 1 and 5. The cDNAs encoding both isoforms 1 and 5 contain the same N-terminal sequence so that the same N-terminal vector can be used to express both isoforms. The vector maps and annotated sequences corresponding to the sequences below are shown in Figures 10-15.

[0096] pTR22-smCBA-otoferlinNT Hs var 1+5-APSD-APhead [ka] [ka] [ka]

change

[0097] pTR22-APhead-APSA-オトフェルリンCT Hs var 1

change

change

change

change

change

[0098] pTR22-APhead-APSA-オトフェルリンCT Hs var 5

change

change

change

change

change

[0099] References 1) A dato A1, Raskin L, Petit C, Bonne-Tamir B Deafness heterogeneity in a Druze isolate from the Middle East: novel OTOF and PDS mutations, low prevalence of GJB2 35delG mutation and indication for a new DFNB locus.Eur J Hum Genet. 2000 Jun;8(6):437-42. 2) Allocca M, Doria M, Petrillo M, Colella P, Garcia-Hoyos M, Gibbs D, Kim SR, Maguire A, Rex TS, Di Vicino U, Cutillo L, Sparrow JR, Williams DS, Bennett J, Auricchio A. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest. 2008 May;118(5):1955-64. 3) Chaib, H., Place, C., Salem, N., Chardenoux, S., Vincent, C., Weissenbach, J., El-Zir, E., Loiselet, J., Petit, C. A gene responsible for a sensorineural nonsyndromic recessive deafness maps to chromosome 2p22-23. Hum. Molec. Genet. 1996 5: 155-158. 4) Choi, B. Y., Ahmed, Z. M., Riazuddin, S., Bhinder, M. A., Shahzad, M., Husnain, T., Riazuddin, S., Griffith, A. J., Friedman, T. B. Identities and frequencies of mutations of the otoferlin gene (OTOF) causing DFNB9 deafness in Pakistan. Clin. Genet. 2009 75: 237-243. 5) Dong B, Nakai H, Xiao W. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther. 2010 Jan;18(1):87-92. 6) Ghosh A, Yue Y, Duan D. Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences. Hum Gene Ther. 2011 Jan;22(1):77-83.

[0100] 7) Hirsch ML, Agbandje-McKenna M, Samulski RJ. Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus. Mol Ther. 2010 Jan;18(1):6-8. 8) Lai Y, Yue Y, Duan D. Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther. 2010 Jan;18(1):75-9. 9) Matsunaga T1, Mutai H, Kunishima S, Namba K, Morimoto N, Shinjo Y, Arimoto Y, Kataoka Y, Shintani T, Morita N, Sugiuchi T, Masuda S, Nakano A, Taiji H, Kaga K. A prevalent founder mutation and genotype-phenotype correlations of OTOF in Japanese patients with auditory neuropathy. Clin Genet. 2012 Nov;82(5):425-32. doi: 10.1111 / j.1399-0004.2012.01897.x. Epub 2012 Jun 1 . 10) Rodriguez-Ballesteros M, del Castillo FJ, Martin Y, Moreno-Pelayo MA, Morera C, Prieto F, Marco J, Morant A, Gallo-Teran J, Morales-Angulo C, Navas C, Trinidad G, Tapia MC, Moreno F, del Castillo I. Auditory neuropathy in patients carrying mutations in the otoferlin gene (OTOF). Hum Mutat. 2003 Dec;22(6):451-6. 11) Roux I, Safieddine S, Nouvian R, Grati M, Simmler MC, Bahloul A, Perfettini I, Le Gall M, Rostaing P, Hamard G, Triller A, Avan P, Moser T, Petit C. Otoferlin, defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse. Cell. 2006 Oct 20;127(2):277-89. 12) Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther. 2010 Jan;18(1):80-6.

[0101] 13) Yasunaga S, Grati M, Chardenoux S, Smith TN, Friedman TB, Lalwani AK, Wilcox ER, Petit C. Am J Hum Genet. OTOF encodes multiple long and short isoforms: genetic evidence that the long ones underlie recessive deafness DFNB9. 2000 Sep;67(3):591-600. Epub 2000 Jul 19. 14) Yasunaga S, Grati M, Cohen-Salmon M, El-Amraoui A, Mustapha M, Salem N, El-Zir E, Loiselet J, Petit C. A mutation in OTOF, encoding otoferlin, a FER-1-like protein, causes DFNB9, a nonsyndromic form of deafness. Nat Genet. 1999 Apr;21(4):363-9. 15) Didier Dulon, Saaid Safieddine, Sherri M. Jones, Christine Petit. Otoferlin is Critical for a Highly Sensitive and Linear Calcium Dependent Exocytosis at Vestibular Hair Cell Ribbon Synapses. J Neurosci. 2009 August. 16) Zippora Brownstein, Yoni Bhonker and Karen B Avraham. High-throughput sequencing to decipher the genetic heterogeneity of deafness. Brownstein et al. Genome Biology 2012, 13:245 17) Rodriguez-Ballesteros et al. (2003) "Auditory neuropathy in patients carrying mutations in the otoferlin gene (OTOF)" Hum Mutat.; 22 (6):451-456. 18) Petersen MB, Willems PJ: Non-syndromic, autosomal-recessive deafness. Clin Genet. 2006; 69 (5): 371-92.

[0102] 19) Smith R, Gurrola J, Kelley P. OTOF-Related Deafness. In: Pagon R, Bird T, Dolan C, Stephens K, eds. Gene Reviews. Seattle: Internet; 2008 20) Roux I, Safieddine S, Nouvian R et al. Otoferlin, defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse. Cell 2006;127:277-89 21) Kral A, O'Donoghue GM: Profound deafness in childhood. N Engl J Med. 2010; 363(15):1438-50. doi: 10.1056 / NEJMra0911225. 22) Dyka FM, Boye SL, Chiodo VA, Hauswirth WW, Boye SE., Dual Adeno-Associated Virus Vectors Result in Efficient In Vitro and In Vivo Expression of an Oversized Gene MY07A, Hum Gene Ther Methods. 2014 ; 25 (2):166-77. doi: 10.1089 / hgtb.2013.212. 23) Akil O, Seal RP, Burke K, Wang C, Alemi A, During M, Edwards RH, Lustig LR: Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy. Neuron. 2012; 75 (2):283-93. doi: 10.1016 / j.neuron.2012.05.019.

[0103] Other aspects All features disclosed herein may be combined in any combination. Each feature disclosed herein may be replaced by alternative features serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features. From the above description, those skilled in the art can easily ascertain the essential features of the present disclosure, and can make various changes and modifications to the disclosure to adapt it to various uses and conditions without departing from the spirit and scope thereof. Accordingly, other embodiments are within the scope of the claims.

[0104] Equivalent While several inventive aspects have been described and illustrated herein, those of ordinary skill in the art will readily conceive of various other means and / or structures for performing the functions and / or obtaining the results and / or one or more of the advantages described herein. Each such variation and / or modification is deemed to be within the scope of the inventive aspects described herein. More generally, those of ordinary skill in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary, and that the actual parameters, dimensions, materials, and / or configurations will depend on the particular application(s) for which the teachings of the invention are being used. Those of ordinary skill in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive aspects described herein. Thus, the foregoing embodiments are presented by way of example only, and it will be understood that within the scope of the appended claims and their equivalents, the inventive aspects may be practiced otherwise than as specifically described and claimed. Inventive aspects of the present disclosure relate to each individual feature, system, article, material, kit, and / or method described herein. Furthermore, any combination of two or more of such features, systems, articles, materials, kits, and / or methods, if such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent, is also included within the inventive scope of the present disclosure.

[0105] All definitions and those used herein should be understood to govern any dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms. All references, patents, and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, and may in some cases include the entire document. The indefinite articles "a" and "an," as used in the specification and claims, unless clearly indicated otherwise, should be understood to mean "at least one."

[0106] The phrase "and / or" as used in the specification and claims should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and / or" should be construed in the same manner, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and / or" clause, whether or not related to the specifically identified elements. Thus, as a non-limiting example, a reference to "A and / or B" when used with open-ended language such as "comprising" may refer in one embodiment to only A (optionally including elements other than B), in another embodiment to only B (optionally including elements other than A), in yet another embodiment to both A and B (optionally including other elements), etc.

[0107] As used herein and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as inclusive, i.e., including at least one, but also including a plurality of the elements of the number or list, and optionally including additional items not included in the list. Only terms expressly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one number or list of elements. In general, the term "or" as used herein will only be interpreted to indicate exclusive alternatives (i.e., "one or the other, but not both") when preceded by a term of exclusivity, such as "either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[0108] As used in the specification and claims, the phrase "at least one" in reference to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but not necessarily including at least one and every element specifically listed in the list of elements, and not excluding any combination of elements in the list of elements. This definition also allows for elements other than the elements specifically identified in the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified, may optionally be present. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently, "at least one of A and / or B") can refer, in one embodiment, to at least one (optionally including more than one) A (wherein B is absent (and optionally including elements other than B)), in another embodiment, to at least one (optionally including more than one) B (wherein A is absent (and optionally including elements other than A)), in yet another embodiment, to at least one (optionally including more than one) A and at least one (optionally including more than one) B (and optionally including other elements), etc.

[0109] It is also to be understood that, unless expressly stated to the contrary, in any method of the claims that includes more than one step or act, the order of the method steps or acts is not necessarily limited to the order in which the method steps or acts are recited. In the claims, as well as in the above specification, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like, are to be understood to be open-ended, i.e., to mean inclusive but not exclusive. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively, as set forth in the U.S. Patent Office Patent Examining Procedures, Section 2111.03.

Claims

1. 1. A composition for use in treating hearing loss or vestibular disorders in a human subject having a mutation in the OTOF gene, comprising: wherein the subject has the following mutations in the OTOF gene: TYR730TER; GLN829TER; PRO1825ALA; PRO50ARG; LEU1011PRO; ILE515THR; ARG1939GLN; GLY541SER; an A to G transition at the intron 8 / exon 9 junction (IVS8-2A-G); a G to A transition at position +1, the first intron nucleotide, in the splice donor site of exon 5; a G to C transversion at the donor splice site of intron 39; a one base pair deletion (1778G) in exon 16 leading to a stop codon, and a 6141G-A change resulting in an ARG to GLN substitution in exon 48; and The composition comprises: a first AAV particle comprising a first polynucleotide; and A second AAV particle comprising a second polynucleotide where (i) the first polynucleotide comprises, from 5' to 3': (a) a promoter, (b) a partial coding sequence encoding the N-terminal portion of an otoferlin polypeptide; (c) a splice donor site, and (d) a first region of homology that contains a sequence homologous to a sequence in a second polynucleotide; and (ii) the second polynucleotide comprises, from 5' to 3': (a) a second region of homology that contains a sequence homologous to a sequence in the first polynucleotide; (b) a splice acceptor site, (c) a partial coding sequence encoding the C-terminal portion of an otoferlin polypeptide; and (d) a polyadenylation (pA) signal sequence; an inverted terminal repeat sequence flanking an expression cassette containing The otoferlin polypeptide is a human otoferlin isoform 5 polypeptide having the sequence of SEQ ID NO:6; and the first region of homology and the second region of homology are between 50 and 300 nucleotides; The composition.

2. 1. A composition for use in treating hearing loss or vestibular disorders in a subject having a mutation in the OTOF gene, comprising: a first AAV particle comprising a first polynucleotide; and A second AAV particle comprising a second polynucleotide where AAV particles are 10 ６ ~10 １４ is the amount of vector genomes / ml, (i) the first polynucleotide comprises, from 5' to 3': (a) a promoter, (b) a partial coding sequence encoding the N-terminal portion of an otoferlin polypeptide; (c) a splice donor site, and (d) a first region of homology that contains a sequence homologous to a sequence in a second polynucleotide; and (ii) the second polynucleotide comprises, from 5' to 3': (a) a second region of homology that contains a sequence homologous to a sequence in the first polynucleotide; (b) a splice acceptor site, (c) a partial coding sequence encoding the C-terminal portion of an otoferlin polypeptide; and (d) a polyadenylation (pA) signal sequence; an inverted terminal repeat sequence flanking an expression cassette containing The otoferlin polypeptide is a human otoferlin isoform 5 polypeptide having the sequence of SEQ ID NO:6; and the first region of homology and the second region of homology are between 50 and 300 nucleotides; The composition.

3. The composition of claim 2 , wherein the subject is a mammal.

4. The composition of claim 3 , wherein the subject is a human.

5. The composition of any one of claims 1 to 4, wherein the first region of homology and the second region of homology comprise the nucleotide sequence of SEQ ID NO:

3.

6. The composition of any one of claims 1 to 5, wherein the promoter is a chimeric CMV / chicken β-actin promoter or a truncated chimeric CMV / chicken β-actin promoter.

7. The composition of claim 6, wherein the promoter comprises a sequence having at least 90%, at least 92.5%, at least 95%, at least 98%, or at least 99% identity to SEQ ID NO:4, or wherein the promoter comprises the sequence of SEQ ID NO:

4.

8. The composition of any one of claims 1 to 7, wherein the splice donor site comprises the sequence of SEQ ID NO:

7.

9. The composition of any one of claims 1 to 8, wherein the splice acceptor site comprises the sequence of SEQ ID NO:

8.

10. The composition of any one of claims 1 to 9, wherein the pA signal sequence is the bovine growth hormone (bGH) pA signal sequence.

11. The composition of any one of claims 1 to 10, wherein the inverted terminal repeat sequence is an AAV2 inverted terminal repeat sequence.

12. The composition of any one of claims 1 to 11, wherein the first and second AAV particles are AAV2 serotype particles.

13. The composition of any one of claims 1 to 12, further comprising a pharma- ceutically acceptable carrier.

14. The composition of any one of claims 1 to 13, wherein the hearing loss or vestibular disorder is DFNB9.

15. A composition according to any one of claims 1 to 14 for use in increasing the expression of otoferlin in a cell.

16. The composition of claim 15 , wherein the cell is in a mammalian subject.

17. Use of a composition according to any one of claims 1 to 16 for the manufacture of a medicament for the treatment of hearing loss.

18. 18. The use according to claim 17, wherein the medicament is for the treatment of DFNB9.

Images